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Abstract 
Background: Artemether/lumefantrine (Coartem®) has been used as a treatment for uncomplicated Plasmodium 
falciparum infection since 2004 in Benin. This open‑label, non‑randomized study evaluated efficacy of artemether–
lumefantrine (AL) in treatment of uncomplicated falciparum malaria in children aged 6–59 months in two malaria 
transmission sites in northwest Benin.
Methods: A 42‑day therapeutic efficacy study was conducted between August and November 2014, in accordance 
with 2009 WHO guidelines. One‑hundred and twenty‑three children, aged 6 months to 5 years, with uncomplicated 
falciparum malaria were recruited into the study. The primary endpoint was parasitological cure on day 28 and day 
42 while the secondary endpoints included: parasite and fever clearance, improvement in haemoglobin levels. 
Outcomes were classified as early treatment failure (ETF), late clinical failure, late parasitological failure, and adequate 
clinical and parasitological response (ACPR).
Results: Before PCR correction, ACPR rates were 87 % (95 % CI 76.0–94.7) and 75.6 %, respectively (95 % CI 67.0–82.9) 
on day 28 and day 42. In each study site, ACPR rates were 78.3 % in Djougou and 73 % in Cobly on day 42. There was 
no ETF and after PCR correction ACPR was 100 % in study population. All treatment failures were shown to be due 
to new infections. Fever was significantly cleared in 24 h and approximately 90 % of parasites where cleared on day 
1 and almost all parasites were cleared on day 2. Haemoglobin concentration showed a slight increase with parasitic 
clearance.
Conclusion: AL remains an efficacious drug for the treatment of uncomplicated falciparum malaria in Benin, 
although higher rates of re‑infection remain a concern. Surveillance needs to be continued to detect future changes 
in parasite sensitivity to artemisinin‑based combination therapy.
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Background
Malaria remains a major public health problem in tropi-
cal regions. According to the World Health Organization 
(WHO), in 2014 there were an estimated 198 million 
cases and 584,000 deaths in children under 5  years of 
age [1]. In Benin, malaria represents the major reason for 
clinical consultation and hospitalization [2]. Early diagno-
sis and prompt treatment of cases are the most important 
strategies for the control and prevention of this disease. 
Unfortunately, Plasmodium falciparum has developed 
resistance to numerous anti-malarial drugs such as chlo-
roquine (CQ) and sulfadoxine–pyrimethamine (SP) [3]. 
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Drug resistance can affect efforts to control malaria, and 
lead to increased malaria-related mortality and morbid-
ity. The WHO now recommends the use of artemisinin-
based combination therapy (ACT) for treatment of 
uncomplicated falciparum malaria in countries where 
the rates of (CQ/SP) drug resistance are high [4]. ACT 
is thus widely promoted as a strategy to counteract the 
increasing resistance of P. falciparum to anti-malarial 
drugs, and to prevent disease transmission through their 
action against gametocytes [5–7]. In Benin, as a result of 
increasing failure rates of treatment with CQ and SP, the 
national anti-malarial drug policy was changed in 2004, 
with the official withdrawal of CQ and SP replaced by 
an artemisinin-based combination (artemether–lume-
fantrine, AL). Currently, ACT remains highly effective 
with rapid effects on fever in almost all settings as long 
as the partner drug in the combination is effective. In 
Africa, several studies demonstrated its efficacy and 
tolerability [8–10] unlike in some regions of Southeast 
Asia where delayed response to ACT has been reported 
[11, 12]. Because of the threat of emergence and spread 
of artemisinin resistance in malaria-endemic countries, 
especially in Africa, in  vivo anti-malarial efficacy stud-
ies are recommended by WHO [13] for monitoring ACT 
efficacy in all countries where ACT has been deployed, 
to ensure its long-term usefulness. In Benin, the Min-
istry of Health, through the National Malaria Control 
Programme (NMCP), has been routinely conducting 
therapeutic efficacy tests (TETs) at several sentinel sites 
located in different parts of the country. The findings of 
these TETs have provided useful data to support changes 
of anti-malarial drug policy in Benin, including the 
change from CQ and SP to AL as stated above. However, 
the original sentinel sites do not cover all the country’s 
settings whereas previous studies with other anti-malar-
ial drugs showed that the rate of adequate clinical and 
parasitological response (ACPR) varies according to loca-
tion. Furthermore, the programme of routine surveillance 
with TETs for ACT has not yet been implemented, and in 
any case does not always include genotypic confirmatory 
tests. To fill this gap, studies were initiated in two settings 
in the northwest of Benin, where routine surveillance has 
never been conducted, in order to provide efficacy data 
on AL according to a standard WHO 42-day follow-up 
therapeutic efficacy protocol [14].
Methods
Study site, design and target population
The study was conducted in Benin between August and 
November 2014 in two health centres: Djougou, 450 km 
from Cotonou (the capital city), and Cobly, 643 km from 
Cotonou. The distance between the two sites is about 
180  km. In the two sites, malaria transmission occurs 
from May to November during the rainy season. Plas-
modium falciparum is the predominant parasite spe-
cies transmitted by Anopheles gambiae s.s. (85  %) and 
Anopheles arabiensis (15  %) [15]. Prevalence of falcipa-
rum infection was 19.1 % in Djougou and 18 % in Cobly 
(unpublished data). This study was designed as a pro-
spective, open-label, non-randomized single-arm trial 
based on the WHO protocol of 2009 [14] and included 
children aged 6–59 months with uncomplicated falcipa-
rum malaria infection.
Sample size
The sample size was determined based on WHO stand-
ard protocol [14]. Considering the unknown proportion 
of treatment failure rate of AL in study sites, the clini-
cal failure rate was assumed to be 50 %, with confidence 
level of 95 % and a precision around the estimate of 5 %. 
A minimum sample of 50 patients was required for the 
study. With a 20  % increase to allow loss to follow-up 
and withdrawals during the 42-day follow-up period, 
60 patients by site were planned to be included into the 
study. The study recruited a total of 123 patients overall.
Screening and recruitment
Children aged six to 59  months who attended the out-
patient department of Djougou and Cobly Health Cen-
tres were screened, and those who met the eligibility 
criteria were enrolled into the study. Inclusion criteria 
included: (1) fever during the past 24 h or fever at presen-
tation (axillary temperature ≥ 37.5 °C); (2) P. falciparum 
mono-infection with parasite density between 2000 and 
200,000 parasite asexual forms per μL of blood identi-
fied by microscopy on blood smears; (3) no evidence of 
a concomitant febrile illness; (4) no signs/symptoms of 
severe malaria as defined by WHO [16]; (5) ability and 
willingness to attend scheduled follow-up visits and sta-
ble residence within the catchment area throughout the 
study period; and, (6) written informed consent from 
parents. Patients with presence of severe malnutrition 
and regular medication which might have interfered with 
anti-malarial pharmacokinetics were not included but 
received appropriate treatment according to the national 
guidelines.
Laboratory methods
Laboratory screening involved a finger prick to collect 
blood samples for detection of malaria parasites by rapid 
diagnostic test (RDT) and microscopy using thick and 
thin smears. Patients who fulfilled the inclusion criteria 
and who had positive RDT results were enrolled in the 
study and sent to the laboratory for collection of blood 
samples, including two blood slides to detect presence 
of malaria parasites, the level of parasitaemia, species, 
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by microscopy, dried blood spots (DBS) on filter papers, 
blood for haemoglobin determination. The filter papers 
were air-dried and stored in self-sealing plastic bags with 
desiccators for further molecular analysis.
Thick and thin smears
Thick and thin blood smears were prepared, stained with 
10 % Giemsa for 10–15 min. Parasite density was deter-
mined by counting the number of asexual parasites per 
200 white blood cells, and calculated per μL using the fol-
lowing formula: numbered parasites × 8000/200 assum-
ing a white blood cell count of 8000 cells/μL [17, 18]. 
Absence of malaria parasite in 200 high power ocular 
fields of the thick film was considered as negative. Detec-
tion of the different parasite species was done on thin 
films. All slides were read in the health centres’ labora-
tory with external quality control of 10 % of the negatives 
slides and all positives in the Reference Laboratory of 
Parasitology of the Centre National Hospitalier Universi-
taire of Cotonou.
Haemoglobin measurement
Finger-pick blood sample was used to measure haemo-
globin using a portable spectrophotometer (Hemo-Con-
trol, EKF-Diagnostic Gmbh, Germany).
Genotyping
Polymerase chain reaction (PCR) analysis was done to 
distinguish recrudescence from new infection on sam-
ple with treatment failure. Nested PCR was conducted 
on paired samples (parasite collected on day 0 and fail-
ure day) to compare two polymorphic genetic markers 
from P. falciparum msp1 and msp2 genes [19, 20]. After 
DNA extraction, PCR was performed using family-spe-
cific primer pairs as previously described [21, 22]. The 
molecular analyses were performed in the Molecular 
Biology Laboratory of the Centre de lutte integrée contre 
le Paludisme.
Treatment and follow‑up
Patients enrolled in the study were treated with AL 
(Coartem®, Novartis Pharmaceuticals, New York, USA 
for Novartis Pharma AG, Basle, Switzerland, manufac-
tured January 2014, expiry date December 2015, Lot: 
F1214), a fixed combination of 20 mg of artemether and 
120 mg lumefantrine in a tablet. The drugs were admin-
istered according to the manufacturer’s recommended 
dose based on the weight of patient. A full course of AL 
consisted of six doses given twice daily. Patients were 
observed for 30 min to ensure that they did not vomit the 
study drug. When vomiting occurred, a repeat dose was 
given after vomiting stopped. Any patient who persis-
tently vomited the study drug, i.e., three times, treatment 
was discontinued and such patient was withdrawn from 
the study, and treated with parenteral quinine accord-
ing to the national guidelines for management of com-
plicated malaria. The day a patient was enrolled and 
received the first dose of AL was designated day 0. Par-
acetamol was given to all patients with body temperature 
greater than or equal to 38  °C. All patients were hospi-
talized within three days (days 0, 1 and 2) and treatment 
was administered orally under direct observation of a 
nurse with fatty food or milk. After three days of treat-
ment, patients returned home and follow-up was done 
for 42 days with scheduled visits on days 3, 7, 14, 21, 28, 
35, and 42 or at another day (unscheduled visits) when 
patient felt unwell. Parents/guardians were informed and 
encouraged to bring the children to the clinic whenever 
they were unwell without waiting for their scheduled 
visits. The study team made home visits as follow-up for 
study participants that were late for their scheduled vis-
its. Patients who travelled to other places and could not 
be traced for scheduled follow-up were withdrawn from 
the study. Patients withdrawn for the re-appearance of 
P. falciparum were treated with quinine 30  mg/kg/day 
in three doses. During the visits, both clinical and para-
sitological assessments were performed. The thick smear 
was performed every 6 h from day 0 to day 2 and once a 
day during the follow-up (day 3, 7, 14, 21, 28, 35, and 42) 
and on any unexpected visit by the patient. Haemoglobin 
measurement was performed at enrolment and day 2, 7, 
28, and 42 to assess the influence of anti-malarial treat-
ment on anaemia.
Outcome classification
The primary endpoint was parasitological cure on day 28 
and day 42 as per WHO protocol of 2009 [14] and sec-
ondary endpoints included parasite and fever clearance, 
improvement in haemoglobin levels at day 42 from the 
day 0 baseline. Treatment outcomes were classified as 
early treatment failure (ETF), late clinical failure (LCF), 
late parasitological failure (LPF), and adequate clinical 
and parasitological response (ACPR) before and after 
PCR correction [14].
Data analysis
Data from both clinical and parasitological assessments 
from the case report for each study participant were 
entered on an individual record and then into the WHO 
standardized Microsoft Excel data collection form [14]. 
This form was used both for data management and analy-
sis. Additional analysis was conducted with Microsoft 
Excel. The data were entered in the Excel database and 
verified by another person using the case report form. 
Treatment outcome was analysed based on Kaplan–
Meier analysis.
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Ethical considerations
Ethical clearance for this study was obtained from the 
National Ethics Committee for Health Research of Min-
istry of Health. Oral and written informed consent was 
obtained from parents or guardians of all patients before 
they were screened for possible inclusion into the study.
Results
A total of 132 and 111 potentially eligible patients from 
Djougou and Cobly, respectively, were screened for par-
ticipation in the study. Following application of inclusion 
criteria, a total of 126 (63 in both sites) were enrolled into 
the study. The causes of non-inclusion of eligible patients 
were: no or low parasite density, refusal to consent, other 
diseases such as respiratory infections, refusal to be hos-
pitalized. Due to three lost-to-follow-up children who 
travelled out of the study area, between days 3 and 7, the 
total analysable population was 123 (Fig.  1), comprising 
37 % female (45/123) and 63 % (78/123) male participants. 
Patients’ mean age was 31.3  ±  13.5  months. The mean 
body temperature at enrolment was 38.7 ± 0.9  °C while 
the mean haemoglobin concentration was 8.9 ± 2.0 g/dL. 
The parasite density ranged from 2028 to 192,715 with a 
mean of 42,329 asexual parasites/μL. Characteristics of 
the study population are detailed in Table 1.
Primary study outcomes
Classification of treatment outcomes (PCR uncorrected 
and PCR corrected) is presented in Table  2. At day 28, 
an ACPR was noted in 87  % without PCR correction 
and in 100  % after PCR correction. On day 42, analy-
sis of PCR uncorrected data estimated ACPR as 75. 6 % 
(CI 66.5–82.6). No patients showed ETF, while LCF 
was reported in 24 study participants (19.5  % CI 12.9–
27.6), with 17 in Cobly and seven in Djougou. LPF was 
observed in six (4.9 % CI 1.8–10.3) of the evaluated study 
population, three cases in Cobly and three in Djougou. 
Kaplan–Meier survival analysis of the PCR uncorrected 
data showed estimates of success of 1.00 between days 0 
and 20; 0.94 from days 21 to 27; 0.87 from days 28 to 34; 
0.79 from days 35 to 41; 0.75 on day 42 (Fig. 2). The PCR 
corrected cure rate showed that 100  % of the patients 
had ACPR to AL treatment. All treatment failures were 
shown to be due to new infections and, therefore the 
Kaplan–Meier survival analysis of the PCR corrected 
data showed estimates of success of 1.00 from days 0 to 
42, translating into an estimate of cumulative failure inci-
dence of 0.00 from days 0 to 42.
Secondary study outcomes
On day 1 post-treatment, 21/123 (17.1  %) slides were 
negative while 101/123 (82.1  %) were negative on 
day 2. On day 3 all slides were negative. This rapid 
decrease of parasitaemia was confirmed by a rapid 
decline of mean parasitaemia during the first 18  h 
(H0  =  41,317 P/µl; H6  =  30,431 P/µl; H12  =  15,280 
P/µl, H18  =  2631 P/µl); the distribution of parasite 
clearance half-lives is presented in Fig.  3 (thick films 
every 6 h). The Figure shows that most individuals had 
clearance half-lives of around 4  h with two individu-
als who had a delay in the speed of parasite clearance 
around 5.5  h. There was a general reduction in fever 
within 24  h of initiation of treatment, and this was 
maintained until the end of the 42-day follow-up, indi-
cating a fever clearance time of 24 h. The haemoglobin 
concentration increased mildly in conjunction with 
parasitic clearance from the blood, however, the mean 
243 Screened
117 excluded
98 had no malaria parasite
10 had parasiteamia <2000
4: refusal to consent
3: respiratory infecon
associated
2: refusal to be
hospitalised
126 enrolled
3 lost to follow
up (they
travelled far
from study site)
123 assessed on day7
123 assessed on day 42
Fig. 1 Profile of patients screened and enrolled in the study
Table 1 Baseline characteristics of study participants
Variable Overall
Number of patients enrolled (n) 123
Age (months) 6–59 months
 Mean (DS) 31.3 ± 13.5
Gender
 Male [n (%)] 78 (63 %)
 Female [n (%)] 45 (37 %)
Body temperature [°C, mean (SD)] 38.7 ± 0.9
 Range 37.8–41
Parasite density [parasite/μL, mean (SD)] 42,329 ± 50,432
 Range 2028–192,715
Haemoglobin [g/dL, mean (SD)] 8.9 ± 2.0
 Range 7.2–16.2
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change in haemoglobin concentration was statistically 
significant from days 2 to 7 (P = 0.0113) and days 7 to 
28 (P = 0.0000) (Fig. 4).
Discussion
AL combination was officially introduced for the treat-
ment of uncomplicated malaria in Benin in 2004. At 
that particular time, the drug was not generally acces-
sible to the population, but it is nowadays distributed to 
all public health facilities largely through collaborative 
efforts involving Benin’s NMCP and its technical and 
financial partners. The study described here was con-
ducted, according to WHO protocol, in children aged 
6–59  months, the group most vulnerable to malaria in 
countries such as Benin where malaria transmission is 
characterized as stable. Before the age of 5  years chil-
dren have not developed effective anti-malarial immu-
nity. Importantly, the follow-up period of 42 days, rather 
than the 28 days frequently used in studies of this type, 
allows assessment of the impact of new infections aris-
ing in each child. In this study an ACPR, without PCR 
Table 2 Treatment outcome
Outcome Day 28 Day 42
PCR uncorrected (IC 95 %) PCR corrected (IC 95 %) PCR uncorrected (IC 95 %) PCR corrected (IC 95 %)
Early treatment failure (ETF) 0 0 0 (0 %)
[0.0–3.0]
0 (0 %)
[0.0–3.9]
Late clinical failure (LCF) 11 (8.9 %)
[4.1–13.7]
0 24 (19.5 %)
[12.9–27.2]
0 (0 %)
[0.0–3.9]
Late parasitological failure (LPF) 05 (4.1 %)
[1.2–9.6]
0 6 (4.9 %)
[1.8–10.3]
0 (0 %)
[0.0–3.9]
Adequate clinical and parasitological 
response (ACPR)
107 (87 %)
[76.0–94.7]
107 (100 %)
[97.2–100]
93 (75.6 %)
[67.0–82.9]
93 (100 %)
[96.1–100]
Total analysis 123 123
Withdrawn 0 0
Loss to follow‑up 3 (2.4 %) 3 (2.4 %)
Total 126 126
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Fig. 3 Distribution of parasite clearance half‑lives
Fig. 4 Distribution of haemoglobin recovery
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correction, was observed in 75.6 % of the overall popu-
lation with no significant difference between the two 
geographically separated study sites (78.3  % Djougou, 
73 % Cobly; P = 0.56). This ACPR rate is higher than the 
33.3 % obtained by Tinto et al. [23] after 42 days of fol-
low-up in children under 5 years treated with AL, likely 
the result of a very high rate of re-infection. No cases of 
ETF were observed in the study presented here. Moreo-
ver, the cases of LCF and LPF observed were all found to 
be the result of re-infections, giving an ACPR of 100 % 
after PCR correction. This result thus confirms that the 
efficacy of the AL combination for first-line treatment of 
uncomplicated falciparum malaria in Beninese children 
under 5 years of age remains acceptably high after more 
than 10 years’ use. However, it is important to consider 
whether using only the markers msp1 and msp2 might 
have contributed to this very low recrudescence rate. 
It is true that the markers recommended by WHO are 
msp1, msp2 and glurp [24], but these markers should be 
genotyped sequentially, from the higher to the lowest 
discriminatory power. Once the analysis of one marker 
has shown a new infection, the analysis should be 
stopped. If no evidence of new infection is detected with 
the first markers, the second marker should be analysed. 
If no new infection is detected, then the third marker 
should be used. This would mean that the result could 
be given with the genotyping of a single marker and the 
low rate of recrudescence in this study cannot be attrib-
uted to the use of only two markers. Furthermore, sev-
eral studies [25, 26] in which three markers were used 
also found very low recrudescence rates. Findings in this 
study are consistent with other therapeutic efficacy stud-
ies with AL conducted both in the past in Benin [27, 28] 
and elsewhere in sub-Saharan African countries (SSA) in 
which the PCR corrected ACPR ranged from 96 to 100 % 
[25, 26, 29, 30]. Participants with re-infections in the 
present study received quinine as a second-line treat-
ment because routine health services in Benin lack the 
means to distinguish between recrudescences and new 
infections. However, it remains unclear whether quinine 
or the same ACT (AL) would be the optimal treatment 
in such cases. Given that nearly all recurrent parasitae-
mias were caused by new infections, it is reasonable to 
imagine that re-treating the child with the same ACT 
regimen, rather than with quinine, would be appropri-
ate. However, other studies using treatment with AL 
after 28 or 42  days follow-up noted further recrudes-
cences suggesting drug failure with, respectively, 82.4, 92 
and 93  % of ACPR after PCR correction [31–33]. Such 
cases of recrudescence necessitate evaluation for mark-
ers of resistance to detect as early as possible evidence 
of the occurrence of artemisinin resistance. In the study 
presented here, a total of 30 cases of LTF were observed 
from day 21 onwards, giving a rate of re-infection of 
24.4 % in the study population. A similarly high re-infec-
tion rate following AL treatment was observed in Zam-
bia with 37 % in Chongwe [29], 20.8 % in Chipata [29], 
30 % in Ndola [33], and more than 25 % in Burkina Faso 
[34]. In Mali [35] a study on the efficacy and safety of 
different ACT found more cases of re-infection with AL 
than with other ACT, such as artesunate–amodiaquine 
(AS + AQ), artesunate and sulfadoxine–pyrimethamine 
(AS +  SP). These results raise the question of the effi-
cacy of lumefantrine, the long-acting partner drug in the 
AL combination that should prevent early re-infections. 
The half-life of artemisinin is approximately 2  h versus 
four to six days for lumefantrine [36, 37], which thereby 
prolongs the antiplasmodial action of the drug combi-
nation. Plausibly then, the occurrence of frequent re-
infections might indicate a decrease in the sensitivity of 
some plasmodial strains to lumefantrine. Such results 
indicate a requirement for regular in vitro monitoring 
of the efficacy of lumefantrine on plasmodial strains in 
countries where the AL combination is used as first-
line treatment. The absence of ETF during treatment 
with AL in this study and in several others [25, 27, 38, 
39] highlights the drug’s efficacy and is emphasized by 
the rapid rate (48  h) of parasite clearance. These find-
ings are similar to those previously reported in studies 
from several other countries [27, 33, 40, 41]. AL clears 
parasites quickly as a result of the rapidly absorbed, fast-
acting artemisinin component. Here, parasite clearance 
half-lives were around 4  h for most individuals with 
rapid decline of mean parasitaemia during the first 18 h, 
results similar to those previously reported in other 
parts of Africa [40–42]. The difference with the study in 
Nigeria [43], where parasitaemia disappeared in all chil-
dren after 16 h, could be explained by the fact that the 
study in Nigeria included children aged 12–132 months, 
i.e., children aged one to 11  years old, many of whom 
will have developed immunity that can synergize with 
drugs to promote the rapid elimination of parasites. In 
this study, having two individuals with delay in clear-
ance half-lives does not undermine the efficacy of AL. 
According to WHO, partial resistance to artemisinin is 
suspected when more than 10 % of patients have a par-
asite clearance half-life longer than 5  h after treatment 
with ACT [44].
Rapid fever clearance was noted in all participants, 
100 % of whom were fever-free within 24 h. Fever clear-
ance kinetics could also be explained by the fast-acting 
parasite clearance properties of artemisinins, leading to 
rapid resolution of symptoms including fever [45]. An 
antipyretic (paracetamol) was given to febrile patients, 
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however no patients in the study required paracetamol 
after 24 h. It is nevertheless important to note that the 
use of paracetamol should be discussed as a confound-
ing factor contributing to fever clearance time of AL. 
Other studies have reported similar findings [25, 26, 33, 
46]. Although AL cleared fever and parasitaemia in a 
very short period of time (less than three days), a con-
comitant significant increase in the concentration of 
haemoglobin was not observed. This less-pronounced 
post-treatment haematological recovery suggests that 
malaria could be the major contributing factor to the low 
haemoglobin levels at enrolment, but that the slow rate 
of recovery may imply that in SSA countries, other fac-
tors, such as geohelminths and malnutrition, may play 
a key role in the occurrence of anaemia as reported in 
other studies [40].
Conclusion
AL remains an effective drug for the treatment of uncom-
plicated falciparum malaria in Benin although higher 
rates of re-infection remain a concern. Ten years after 
its introduction as a first-line drug, AL remains effective, 
rapidly clearing fever and parasites within 48 h. Regular 
surveillance should to be continued in these and other 
sites in the country to provide early warnings of changes 
in parasite sensitivity to ACT. To reduce the burden of 
malaria, the efficacy of AL, of other ACT and of their 
partner drugs needs to be carefully and periodically mon-
itored in order to provide the evidence-base for timely 
reviews of malaria treatment policy.
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